AbbVie (ABBV)
(Delayed Data from NYSE)
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $197.01 +0.19 (0.10%) 8:54 AM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $197.01 +0.19 (0.10%) 8:54 AM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib
by Zacks Equity Research
AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of adult patients with moderate to severe rheumatoid arthritis.
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study
by Zacks Equity Research
Eli Lilly's (LLY) Taltz displays superiority over standard of care medicine Humira in a head-to-head study on patients with active psoriatic arthritis.
The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney
AbbVie (ABBV) Stock Moves -0.79%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $84.93 in the latest trading session, marking a -0.79% move from the prior day.
Top Stocks Reports for McDonald's, AbbVie & Altria
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), AbbVie (ABBV) and Altria (MO).
Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
by Zacks Equity Research
Gilead Sciences (GILD) names Roche's Daniel O'Day as the company's new Chairman and CEO.
Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800
by Zacks Equity Research
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day.
Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend
by Zacks Equity Research
Amgen (AMGN) hikes its quarterly dividend by 10%.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
by Zacks Equity Research
IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.
Gilead's (GILD) Harvoni and Descovy Get Approval in China
by Zacks Equity Research
Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.
J&J's Blood Cancer Drugs Succeed in Label Expansion Studies
by Zacks Equity Research
J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.
Roche Announces Positive Data on Venclexta/Venclyxto at ASH
by Zacks Equity Research
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.
AbbVie Settles With Pfizer for Humira Biosimilar in U.S.
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November
AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
by Zacks Equity Research
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.
Why Is AbbVie (ABBV) Up 17.5% Since Last Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Key Pharma Players With HIV Focus Ahead of World Aids Day
by Indrajit Bandyopadhyay
We take a look at some of the major pharma companies in the HIV market that are developing drugs to address the life-threatening disease.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $88.93 in the latest trading session, marking a +1.43% move from the prior day.
Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth
by Zacks Equity Research
Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
Roche, AbbVie Get FDA Approval for Venclexta Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets accelerated approval for Venclexta for the treatment of patients suffering from newly-diagnosed AML who are aged 75 years or older.